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Glycemic variability constitutes a major driving force for
pancreatic ductal adenocarcinoma local invasion, angiogen-
esis, and metastatic colonization. Through epigenetic ma-
chinery, retinoic acid signaling acts as a critical sensor of
glycemic variability that relays the glycemic signal to pro-
metastatic Runx3/Col6a1 pathway.
BACKGROUND & AIMS: Although nearly half of pancreatic
ductal adenocarcinoma (PDAC) patients have diabetes mellitus
with episodes of hyperglycemia, its tumor microenvironment is
hypoglycemic. Thus, it is crucial for PDAC cells to develop
adaptive mechanisms dealing with oscillating glucose levels. So
far, the biological impact of such glycemic variability on PDAC
biology remains unknown.
METHODS: Murine PDAC cells were cultured in low- and high-
glucose medium to investigate the molecular, biochemical, andmetabolic inﬂuence of glycemic variability on tumor behavior.
A set of in vivo functional assays including orthotopic implan-
tation and portal and tail vein injection were used. Results were
further conﬁrmed on tissues from PDAC patients.
RESULTS: Glycemic variability has no signiﬁcant effect on
PDAC cell proliferation. Hypoglycemia is associated with local
invasion and angiogenesis, whereas hyperglycemia promotes
metastatic colonization. Increased metastatic colonization un-
der hyperglycemia is due to increased expression of runt
related transcription factor 3 (Runx3), which further activates
expression of collagen, type VI, alpha 1 (Col6a1), forming a
glycemic pro-metastatic pathway. Through epigenetic machin-
ery, retinoic acid receptor beta (Rarb) expression ﬂuctuates
according to glycemic variability, acting as a critical sensor
relaying the glycemic signal to Runx3/Col6a1. Moreover, the
signal axis of Rarb/Runx3/Col6a1 is pharmaceutically acces-
sible to a widely used antidiabetic substance, metformin, and
Rar modulator. Finally, PDAC tissues from patients with dia-
betes show an increased expression of COL6A1.
430 Jian et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 4CONCLUSIONS: Glycemic variability promotes both local inva-
sion and metastatic colonization of PDAC. A pro-metastatic
signal axis Rarb/Runx3/Col6a1 whose activity is controlled
by glycemic variability is identiﬁed. The therapeutic relevance
of this pathway needs to be explored in PDAC patients, espe-
cially in those with diabetes. (Cell Mol Gastroenterol Hepatol
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PDAC has a bi-directional connection with diabetes melli-
tus,2,3 with diabetes being both a risk factor and an early
sign of the disease; nearly 50% of PDAC patients have dia-
betes at the time of diagnosis.4 PDAC patients with diabetes
tend to have larger tumors and worse prognosis.5–7 PDAC is
poorly vascularized, and its tumor microenvironment is
hypoxic and severely hypoglycemic.8 Thus, PDAC cells
(particularly those in diabetic patients) are likely to expe-
rience oscillating extracellular glucose levels. So far, the
biological signiﬁcance of transient presumed hypoglycemia
and hyperglycemia in pancreatic carcinogenesis remains
undeﬁned.
Recent sequencing results of human PDAC have un-
covered a limited heterogeneity in the genomes of primary
tumors and metastases; the metastatic lesion has the same
driver gene mutation as its primary cancer. In particular,
no metastasis-speciﬁc driver mutation was discovered.9
This raises an important question: what is the driving
force triggering early metastasis. In this regard, a recent
landmark study demonstrated that metastatic PDAC car-
ried a distinctive large-scale reprogramming of chromatin
modiﬁcations targeting genes related to anabolic glucose
metabolism,10 underscoring the importance of the
metabolic–epigenetic program for glucose metabolism in
promoting PDAC metastases. These ﬁndings are in line
with clinical observations that PDAC metastases are largely
tropic for organs (liver, lung) with glucose replete condi-
tion relative to hypoglycemic primary tumors.11
Collagen, type VI, alpha 1 (Col6a1) is a secreted pro-
metastatic mediator promoting metastatic colonization of
PDAC,12,13 whose expression is speciﬁcally controlled by
runt related transcription factor 3 (Runx3), forming a
distinct pro-metastatic signaling axis. In PDAC, Runx3
expression is affected by 2 major driver mutations, p53
(TP53) and Smad4.12,13 Here, Runx3 is induced by either
p53 gain-of-function mutation or complete loss of Smad4. In
other biological contexts, Runx3 has been previously shown
to be activated by retinoic acid (RA) signaling.14,15 Although
RA signaling and its receptors are dysregulated in
PDAC,16,17 it is unclear whether RA-mediated Runx3 acti-
vation is functionally relevant in promoting a metastatic
phenotype of PDAC.
Here we investigated the biological impact of glycemic
variability on PDAC cells. This analysis reveals that hypo-
glycemia is associated with local invasion and angiogenesis,
whereas hyperglycemia promotes metastatic colonization.The phenotypic difference in metastatic colonization is due
to the increased expression of Runx3/Col6a1. Further
analysis identiﬁes RA signaling as the key glucose-sensing
pathway that promotes Runx3/Col6a1 expression, which
is operated by epigenetically regulated retinoic acid recep-
tor beta (Rarb) expression. Moreover, this glycemic pathway
is pharmaceutically accessible by using metformin or Rar
modulator. Finally, PDAC sections from patients with dia-
betes show increased expression of COL6a1. These data
deﬁne the signal axis of Rarb/Runx3/Col6a1 as a potential
target for PDAC patients with diabetes.
Results
Glycemic Variability Has No Effect on Pancreatic
Ductal Adenocarcinoma Proliferation
Previously, we characterized a highly metastatic mouse
model of PDAC that was driven by one allele loss of tuber-
ous sclerosis 1 together with pancreas-speciﬁc oncogenic
KrasG12D expression (p48Cre; KrasG12D/þ; Tsc1-/þ).18–20 A
particular signature of "Mek/Erk-mTOR" was identiﬁed by
using cancer cell lines from those animals. The Kyoto
Encyclopedia of Genes and Genomes pathway analysis of
this signature uncovered the glucose-related metabolism as
the major enriched pathway.20 Thus, we chose one repre-
sentative cell line, 399 cells (showing epithelial-like
morphology in 2-dimensional culture system), to investi-
gate the biological inﬂuence of glycemic variability on tumor
behavior (Figure 1A).
First, we tested the inﬂuence of glycemic variability on
anchorage-dependent growth by culturing 399 cells in me-
dium supplemented with 10% non-dialyzed fetal bovine
serum (FBS) containing 2 mmol/L glutamine and a range
of glucose levels. Here, neither high levels of glucose
(25 mmol/L) nor previously deﬁned low levels of glucose
(0.5 mmol/L) had signiﬁcant effects (Figure 1B)21; thus we
chose medium containing 0.5 mmol/L medium as hypogly-
cemia culture medium for further experiment. Even after
long-term culturing in low-glucose medium (>30 days), no
difference in cell proliferation was observed (as determined
by MTT and live cell counting assays; Figure 1C and D).
Furthermore, no difference in the apoptotic and necrotic
rates was found by ﬂuorescence-activated cell sorting
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low-glucose medium showed around 50% decrease in
glucose uptake compared with those in high-glucose me-
dium (Figure 1F, P ¼ .0002). A ﬂudeoxyglucose F 18 uptake
assay based on microﬂuidic system conﬁrmed these results
by showing a real-time reduction in glucose uptake in PDAC
cells maintained in low-glucose medium22 (Figure 1G). The
reduced glucose uptake was reﬂected in reduced glycolytic
activity as judged by extracellular acidiﬁcation rates. The
simultaneous assessment of cellular respiration by plate-
based respirometry revealed no differences in mitochon-
drial energy turnover (Figure 1H). The reduced metabolic
status of PDAC cells in low glucose was seen in lower
adenosine triphosphate (ATP) and adenosine diphosphate
(ADP) concentrations (Figure 1I) but without changing the
ADP/ATP ratio (Figure 1J). Taken together, glycemic vari-
ability has no effect on cell proliferation; PDAC cells main-
tained in high-glucose medium (25 mmol/L) were deﬁned
as hyperglycemic PDAC cells, whereas PDAC cells main-
tained in low-glucose medium (0.5 mmol/L) were deﬁned
as hypoglycemic PDAC cells.Hypoglycemia Is Associated With Local Invasion/
Angiogenesis and Hyperglycemia Promotes
Metastatic Colonization
First, we performed orthotopic injection to determine
the in vivo phenotype of PDAC cells maintained in hyper-
glycemic and hypoglycemic conditions. Although no differ-
ence in tumor size and stroma density was observed,
tumors formed by hypoglycemic PDAC cells contained less
tumor necrosis (Figure 2A, validated by cleaved-caspase 3
and carbonic anhydrase IX (Caix) staining, Figure 2B). The
proliferation rate was similar (Figure 2C). As determined by
CD31 staining, microvessel density was signiﬁcantly
elevated in tumors formed by hypoglycemic PDAC cells
compared with those formed by hyperglycemic PDAC cells
(Figure 2D). In line, hypoglycemic PDAC cells secreted a
higher amount of vascular endothelial growth factor A, a
potent pro-angiogenic factor, compared with hyperglycemic
cells (Figure 2E). Transcriptome analysis revealed that
genes related to the regulation of angiogenesis and vascu-
lature development were mostly enriched in hypoglycemic
PDAC cells (as determined by Gene Ontology; Figure 2F,
Table 1). Meanwhile, hypoglycemic PDAC cells gave rise to
tumors showing a locally more invasive phenotype. The
pathological analysis revealed that the ratio of the solid
(dedifferentiated) versus ductal component was higher in
the hypoglycemic cells–derived tumors than the hypergly-
cemic ones. This was also reﬂected by the staining pattern
of E-cadherin. The quantitative analysis revealed that the
tumor area negative for E-cadherin staining was signiﬁ-
cantly larger in hypoglycemic cells–derived tumors
(Figure 2G). In vitro invasion and migration assays
conﬁrmed that hypoglycemic PDAC cells were more invasive
than hyperglycemic cells (Figure 2H).
To characterize the hepatic metastatic colonization of
hypoglycemic and hyperglycemic PDAC cells, we performedportal vein injections. Here, the percentage of the area of
hepatic metastasis in hyperglycemic PDAC cells was 5-fold
higher than that of hypoglycemic cells (Figure 3A, P ¼
.0068). To further validate these results, we performed tail
vein injections to assess the pulmonary colonization of these
cells. As determined by standardized uptake values, a
quantitative analysis using positron emission tomography
(PET)–computed tomography (CT) scans, the pulmonary
metastasis load of animals injected with hyperglycemic
PDAC cells was 2.48% ± 0.24% IDg, which was higher than
that of hypoglycemia cells (0.88% ± 0.02% IDg; Figure 3B
and C, P ¼ .02), which was conﬁrmed by histologic analysis
(Figure 3D). Because of signiﬁcant difference in metastatic
colonization, we repeated the experiments in 3 other murine
PDAC cell lines: 634 cells established also from p48Cre;
KrasG12D/þ; Tsc1-/þ mice; less metastatic 1050 cells isolated
from p48Cre; KrasG12D/þ; p53-/þ mice; and 10069 cells con-
taining a p53R172H mutation obtained from Pdx1Cre;
KrasG12D/þ; p53R172H/þ mice.20 Consistently, this analysis
revealed that the hypoglycemia dramatically inhibited met-
astatic capacities of 634 and 1050 cells (Figure 3E and F).
However, no effect was observed in 10069 cells (Figure 3G).
Taken together, these data demonstrate that hypoglyce-
mia is associated with local invasion/angiogenesis, whereas
hyperglycemia promotes metastatic colonization.Collagen, Type VI, Alpha 1 Is Regulated
by Glycemic Variability to Promote
Metastatic Colonization
Because a pronounced difference in metastatic coloni-
zation between hypoglycemic and hyperglycemic PDAC cells
was observed, we investigated the underlying molecular
mechanism responsible for this difference in metastatic
colonization. An anoikis assay was performed to test the
ability of hypoglycemic and hyperglycemic PDAC cells to
survive under anchorage-independent conditions, which is
the ﬁrst step after extravasation to form metastatic coloni-
zation.23 This analysis revealed no difference (Figure 4A),
excluding the anoikis effect on hypoglycemic and hyper-
glycemic PDAC cells. Because previously published data
showed extracellular matrix (ECM) plays an important role
in mediating metastatic colonization,12,24 we evaluated ECM
protein expression under anchorage-independent condi-
tions by using a polymerase chain reaction (PCR) array.
Interestingly, 3 previously deﬁned pro-metastatic ECM me-
diators, Col6a1, secreted phosphoprotein 1, also known as
osteopontin, and ﬁbronectin 1, were up-regulated in hy-
perglycemic PDAC cells at mRNA levels (conﬁrmed by in-
dependent quantitative real-time polymerase chain reaction
[qRT-PCR] assays; Figure 4B and C).12 However, only the
change of Col6a1 could be conﬁrmed on protein levels (as
determined by Western blot analysis in cell lysates and
densitometry analysis; Figure 4D and E). To test the func-
tional relevance of Col6a1 in mediating metastatic coloni-
zation, we overexpressed Col6a1 in hypoglycemic PDAC
cells by transfecting a Col6a1-expressing vector and down-
regulated its expression in hyperglycemic PDAC cells by
432 Jian et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 4transfecting a Col6a1-shRNA vector. This analysis revealed
that Col6a1 overexpression restored the metastatic capacity
of hypoglycemic PDAC cells (Figure 4F and G, P ¼ .0072),
whereas Col6a1 down-regulation inhibited the metastatic60
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2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 433Col6a1 had no effect on glucose uptake in hypoglycemic and
hyperglycemic PDAC cells (Figure 4K).Collagen, Type VI, Alpha 1 Is Controlled by the
Retinoic Acid Receptor Beta/Runt Related
Transcription Factor 3 Signal Axis
Next, we set out to investigate the molecular mechanism
underlying increased Col6a1 expression in hyperglycemic
cells. The transcription factor Runx3 controls the expression
of Col6a1 via direct binding to its promoter, forming a
distinctive pro-metastatic signal axis.12 Here we show that
the expression of Runx3 (rather than Runx1 or Runx2) is
increased in hyperglycemic PDAC cells (Figure 5A and B).
Furthermore, this hyperglycemia-associated elevation in
Runx3/Col6a1 expression was conﬁrmed in another cell line
(634 cells, Figure 5C).
Because it has been previously demonstrated that Runx3
expression is affected by Smad4 and p53 status,12,13 we
compared the expression of p53 and Smad4 (SMAD Family
Member 4) between hypoglycemic and hyperglycemic PDAC
cells. As such, no difference was found (Figure 5D). We set
out to look for an alternative mechanism. In this regard, it
has been shown that Runx3 can be induced by all-trans-
retinoic acids in a RA receptor–dependent manner.12,13
Thus, we tested the expression of retinoic acid receptor
alpha, Rarb, retinoic acid receptor gamma, and early growth
response 2 (Egr2) (a downstream target of RA signaling) in
hypoglycemic and hyperglycemic PDAC cells.17 This analysis
revealed that the expression of Rarb and Egr2 was
dramatically increased in hyperglycemic PDAC cells as
compared with that in hypoglycemic cells (Figure 5E). In
line, a slightly increased expression of retinoic acid receptor
gamma was also observed (Figure 5F, left panel). However,
no difference in the expression of retinoic acid receptor
alpha was seen (Figure 5F, right panel). Furthermore, the
intracellular uptake of RA was also higher in hyperglycemic
PDAC cells (Figure 5G, as determined by mass spectrometry
analysis), suggesting an activated RA signaling. To further
conﬁrm this, we treated PDAC cells with a pan-Rar antag-
onist (AGN193109) to inhibit the activity of Rar receptors.
Indeed, inhibition of Rar receptors reduced the expression
of Rarb, Runx3, and Col6a1 in PDAC cells (Figure 5H and I).
In summary, Rarb/Runx3/Col6a1 signal axis constitutes anFigure 1. (See previous page). Glycemic variability has no effe
and 634 cells in 2-dimensional culture system; scale bars, 25 m
tative pictures (right panel) show glycemic variability has no e
proliferation rate after long-term culturing in high-glucose (H) an
similar proliferation rate of hyperglycemic (H) and hypoglycemic
iodide (PI) demonstrates comparable apoptotic and necrotic ra
(F and G) 2DG and 18F-ﬂudeoxyglucose–based glucose uptake a
and low-glucose cultured PDAC cells. (H) Oxygen consumption
show mitochondrial respiration and glycolytic activity, respect
(I and J) ATP, ADP, and ADP/ATP ratio analysis determine basic
cultured PDAC cells. All data are presented as mean ± standard
Unpaired t test is used to examine statistical signiﬁcance, *P <important pro-metastatic signal axis whose activity is
affected by glycemic variability.Retinoic Acid Receptor Beta Relays the Signal of
Glycemic Variability to Runt Related Transcription
Factor 3/Collagen, Type VI, Alpha 1 via
Epigenetic Regulation
Previous studies suggested that an epigenetic-metabolic
interplay played a key role in tumorigenicity.25 As for PDAC,
a recent study demonstrated that the epigenetic-metabolic
control of genes responsible for anabolic glucose meta-
bolism promoted PDAC metastases.10 Using chromatin
immunoprecipitation analysis, we analyzed the promoter of
Rarb for occupation of a set of repressive (H3K27me3,
H3K9me2, and H2AK119ub) and activating (H3K4me3 and
H3K27ac) histone modiﬁcation markers in hypoglycemic
and hyperglycemic PDAC cells (Figure 6A). This analysis
revealed that the Rarb promoter in hyperglycemic PDAC
cells possessed lower levels of repressive histone markers
H3K9me2 and H2AK119ub as compared with hypoglycemic
cells. No difference was found for other histone modiﬁcation
markers (Figure 6B). In line, inhibition of histone deacety-
lases by Vorinostat (also known as SAHA) reconstituted the
expression of Rarb, Runx3, Col6a1, and Egr2 in hypoglyce-
mic PDAC cells (Figure 6C). In line, the histone deacetylase
inhibition led to the signiﬁcantly increased occupation levels
of acetylated histone marker (H3K27ac) on Rarb promoter
but not the methylated histone markers (Figure 6D).
Furthermore, methylation-speciﬁc PCR analysis (tar-
geted at the Rarb promoter CpG island) uncovered that
these CpG islands were highly methylated in hypoglycemic
PDAC cells (Figure 7A). After decitabine treatment (an in-
hibitor of DNA methylation), the expression of Rarb,
Runx3, and Col6a1 was also reconstituted (Figure 7B). No
difference in the expression of Egr2 was found. In addition,
these histone modiﬁcations seemed to be long-lasting in
that a short-term restoration (2 weeks) of hyperglycemic
conditions was not able to reverse the suppressed
expression of Runx3/Col6a1 in hypoglycemic cells
(Figure 7C). Collectively, these data demonstrated that the
epigenetic-metabolic control of Rarb was responsible for
relaying signal of glycemic variability to Runx3/Col6a1
signal axis.ct on PDAC proliferation. (A) Representative pictures of 399
mol/L. (B) Colony formation results (left panel) and represen-
ffect on cell proliferation. (C) MTT assay shows comparable
d low-glucose (L) medium. (D) Live cell counting results show
(L) PDAC cells. (E) FACS analysis for annexin V and propidium
tes of hyperglycemic (H) and hypoglycemic (L) PDAC cells.
ssays determine glucose uptake rate in high-glucose cultured
rate (OCR) and extracellular acidiﬁcation rate (ECAR) analysis
ively, in high-glucose and low-glucose cultured PDAC cells.
cellular energy homeostasis in high-glucose and low-glucose
deviation; data from 3 independent experiments are shown.
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Table 1.Gene Ontology (GO) Terms Analysis
GOBPID P value Count Size Term
1 GO:0052547 1.05E-06 12 319 Regulation of peptidase activity
2 GO:0010466 5.79E-06 9 199 Negative regulation of peptidase activity
3 GO:0045765 7.83E-06 8 156 Regulation of angiogenesis
4 GO:0001525 8.09E-06 11 324 Angiogenesis
5 GO:0001944 1.47E-05 13 484 Vasculature development
6 GO:1901342 1.53E-05 8 171 Regulation of vasculature development
7 GO:0051346 2.16E-05 10 295 Negative regulation of hydrolase activity
8 GO:0044767 6.75E-05 42 3722 Single-organism developmental process
9 GO:0032502 7.54E-05 42 3739 Developmental process
10 GO:0043086 9.28E-05 12 499 Negative regulation of catalytic activity
2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 435The Activity of Retinoic Acid Receptor
Beta/Runt Related Transcription Factor
3/Collagen, Type VI, Alpha 1 Signal
Axis Could Be Modulated by Metformin
We hypothesized that the signal axis of Rarb/Runx3/
Col6a1 permissive to glycemic variability was more likely to
be relevant in PDAC patients who had diabetes. Thus, we
stained a cohort of consecutive PDAC sections for RARB,
RUNX3, and COL6A1. Although no correlation between
either RARB or RUNX3 staining and diabetes was observed
(Figure 8A and B), COL6A1 staining was positive in 88.9% of
diabetic PDAC samples (24/27), which was signiﬁcantly
higher compared with 67.9% in nondiabetic PDAC samples
(38/56) (Figure 8C, P ¼ .039). Using a diabetic mouse
(induced by streptozotocin treatment), we observed that
diabetes indeed promoted metastatic colonization
(Figure 8D, P ¼ .0277).
Because metformin is a widely used antidiabetic sub-
stance associated with favorable prognosis in diabetic pa-
tients with PDAC,26–28 we tested whether the glycemic
Rarb/Runx3/Col6a1 pathway is affected by metformin. A
glucose uptake inhibitor 2-deoxy-D-glucose (2DG) was also
tested. Here, metformin consistently reduced the expression
of Rarb, Runx3, and Col6a1, and it decreased the glucose
uptake of PDAC cells (Figure 9A–D), showing a similar effect
of hypoglycemic culturing. In addition, Runx1, retinoic acidFigure 2. (See previous page). Hypoglycemia links with loc
pictures show larger necrotic area in tumors formed by hyperglyc
(L), hypoglycemic cells; scale bar: 100 mm. (B) Representative IH
panel) show tumor necrosis in tumors formed by hyperglycemic
glucose. (C) Representative IHC pictures of phospho-histone
demonstrate the proliferation status in vivo, scale bar: 100 mm.
microvessel density calculation (right panel) demonstrate incre
scale bar: 100 mm. (E) Vascular endothelial growth factor type A
endothelial growth factor type A secretion in hyperglycemic an
angiogenesis indicated on the right; voxel color: transcriptiona
with the mean. (G) Representative IHC pictures (left panel) and qu
loss in tumors derived from hypoglycemic (L) cells compared
migration (right panel) assay demonstrate invasion and migratio
in vitro. All data are presented as mean ± standard deviation, an
test is applied, *P < .05.receptor alpha, and Egr2 were also found to be reduced by
metformin treatment (Figure 9C). As an internal control,
protein kinase ADP-activated catalytic subunit alpha 1 was
activated by metformin (Figure 9B). Except for Runx3, 2DG
reduced the expression of Rarb and Col6a1 (Figure 9A and
B). Finally, metformin treatment signiﬁcantly impaired the
hepatic metastasis of hyperglycemic PDAC cells (Figure 9E,
P ¼ .0457). Mechanistically, chromatin immunoprecipitation
analysis revealed that metformin treatment increased the
occupation levels of a suppressive histone marker H3K27me
on the Rarb promoter; no difference on either H3K9me2 or
H3K27ac was found (Figure 9F).
Discussion
In this study, we provided descriptive and functional
evidence deﬁning the glycemic variability as major driving
force for PDAC local invasion, angiogenesis, and metastatic
colonization. A well-deﬁned pro-metastatic pathway,
Runx3/Col6a1, was found to be affected by glycemic vari-
ability. Through epigenetic machinery, RA signaling acts as a
critical sensor of glycemic variability that relays the glyce-
mic signal to oncogenic Runx3/Col6a1 expression. This was
achieved through epigenetically regulated Rarb receptor
expression. Finally, the signal axis of Rarb/Runx3/Col6a1
was pharmaceutically accessible to metformin and Rar
modulator.al invasion/angiogenesis. (A) Representative H&E staining
emic cells; high glucose (H), hyperglycemic cells; low glucose
C pictures of cleaved-caspases 3 (left panel) and Caix (right
(H) and hypoglycemic (L) PDAC cells; H, high glucose; L, low
H3 (pH-H3, left panel) and quantitative analysis (right panel)
(D) Representative pictures of CD31 staining (left panel) and
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antitative analysis (right panel) show higher rate of E-cadherin
with hyperglycemic (H) cells. (H) Invasion (left panel) and
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2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 437In essence, we uncovered a novel mechanism deﬁning
Runx3/Col6a1 as the central player in coupling glucose
metabolism with PDAC metastatic colonization. Interest-
ingly, Runx2 was previously reported to favor glucose up-
take and promote synthesis of type I collagen in
osteoblasts.29 Although no difference was observed in
Runx2 in our analysis, these data collectively highlight a
particular role of the Runx family in linking glucose meta-
bolism and synthesis of ECM proteins. As for Runx3, a
context-dependent role was previously reported in PDAC; it
suppresses cell proliferations by inducing expression of
cyclin-dependent kinase inhibitor 1A (also known as p21)
but promotes distant colonization via up-regulating a
number of pro-metastatic mediators including Col6a1. Thus,
patients with high RUNX3 levels are at increased risk for
metastatic disease, whereas the ones with lower RUNX3
levels are prone to have a locally destructive disease.12,13 On
the basis of phenotypic analysis of different transgenic
mouse models, it is proposed that p53 acts cooperatively
with Smad4 in determining Runx3 levels: (1) wild-type p53
induces Runx3 degradation, whereas p53 gain-of-function
mutation stabilizes Runx3; (2) a single-allele loss of
Smad4 decreases Runx3 expression, whereas the double-
allele loss of Smad4 promotes Runx3 expression. We re-
ported that Runx3 levels were also subjected to glucose
metabolism, adding another layer of complexity to the
existing scenario.
Nevertheless, our data demonstrate that the microenvi-
ronmental hypoglycemia constitutes the initial driving force
for invasive growth and angiogenesis; however, these early
disseminating cells may not be able to establish metastases
immediately because of the lack of ability in metastatic
colonization. In line, this is also achieved by epigenetically
down-regulated Rarb expression, which decreases the ac-
tivity of a pro-metastatic Runx3/Col6a1 signal. However,
this loss of capacity in colonization can be overcome by
systemic hyperglycemia (eg, diabetes), genetic mutations
(eg, p53 mutation), and other alternative metastatic path-
ways (eg, formation of a pre-metastatic niche).24
Metformin is a widely used antidiabetic oral medication.
Long-term use of metformin not only decreases PDAC
risk30,31 but is also associated with improved patient
survival.26–28 We demonstrated that the pro-metastatic
pathway of Rarb/Runx3/Col6a1 axis could be directly/
indirectly affected by metformin, which may contribute to
its beneﬁciary effect. Despite these encouraging results, the
addition of metformin to the conventional chemotherapy
did not improve outcome in patients with metastatic PDAC
in two phase II trials.32,33 A possible explanation is that theFigure 3. (See previous page). Hyperglycemia promotes meta
(left panel) and metastatic area calculation (right panel) show hep
Representative PET-CT scan and reconstructed 3-dimensional
hypoglycemic cells. (C) Quantitative analysis of average standa
perglycemic and hypoglycemic cells. (D) Representative picture
hyperglycemic PDAC cells. (E–G) Representative H&E staining p
show hepatic colonization of hyperglycemic and hypoglycemic 6
presented as mean ± standard deviation, and data from 3 ind
examine statistical signiﬁcance, *P < .05.patients involved in the clinical trials were in metastatic
stage. The disseminating PDAC cells evading from their
primary hypoglycemic niches have likely overcome the
defect in remote colonization. Thus, it is likely that metfor-
min needs to be offered at the early stage of disease or as an
adjuvant agent.34 In addition, RAR inhibitors have been
previously shown to have anti-metastatic properties in
PDAC.35 Thus, it is reasonable to speculate that a combi-
nation of highly selective RAR modulators (eg, against
RARB) and metformin might be more effective in inhibiting
PDAC metastasis.36 This is particularly important for PDAC
patients with diabetes.
Materials and Methods
Cell Culture
High-glucose medium was commercially available
(glucose 25 mmol/L, D5796; Sigma-Aldrich, Munich, Ger-
many). Low-glucose medium was prepared by using glucose-
free Dulbecco modiﬁed Eagle medium (11966025; Thermo
Fischer Scientiﬁc, Dreieich, Germany) supplemented with
0.5 mmol/L D(þ)-Glucose (X997.1; Carl Roth, Karlsruhe,
Germany). All PDAC cells were cultured with speciﬁc condi-
tional medium supplemented with 10% FBS (F0804; Sigma-
Aldrich), 100 U/mL penicillin, and 100 mg/mL streptomycin
at 37ºC, 5% CO2. The non-dialyzed FBS was used, which
contained 1.1 ± 0.1 mmol/L glucose. Thus, the actual glucose
concentration in medium containing 10% FBS is 0.1 mmol/L
higher than the presumed ones.
Primary Tumor Cell Isolation
Primary tumor cells were isolated from genetically engi-
neered mice with the genotypes of p48Cre; LSL-KrasG12D/þ;
Tsc1ﬂ/þ (399 and 634 cells), p48Cre; LSL-KrasG12D/þ; p53-/þ
(1050 cells) and Pdx1Cre; LSL-KrasG12D/þ; p53R172H/þ (10069
cells), as previously described.20 In brief, dissected tumor
tissues were cut into small pieces and incubated with culture
medium supplemented with 1.2 mg/mL collagenase (C6885-
1G; Sigma-Aldrich) at 37C for 30–40 minutes. Afterwards,
the collagenase was washed out by using collagenase-free
culture medium with centrifugation at 300 rpm for 5 mi-
nutes. After an additional collagenase incubation and
washout, the achieved cell suspensions were seeded into a
10-cm2 dish with complete culture medium.
Inhibitor Treatment Experiment
PDAC cells were treated with either 20 mmol/L
metformin hydrochloride (PHR 1084; Sigma-Aldrich) or
2 mmol/L 2DG (D8375; Sigma-Aldrich) for 48 or 72 hours.static colonization. (A) Representative H&E staining pictures
atic colonization of hyperglycemic and hypoglycemic cells. (B)
pictures show pulmonary colonization of hyperglycemic and
rd uptake value demonstrates pulmonary colonization of hy-
s of H&E staining show increased pulmonary colonization by
ictures (left panel) and metastatic area calculation (right panel)
34, 1050, and 100369 cells (n  3 for each group); All data are
ependent experiments are shown. Unpaired t test is used to
438 Jian et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 4Hypoglycemic PDAC cells were treated with 10 or 20 mmol/L
Vorinostat (also known as SAHA, SML0061; Sigma-Aldrich),
50 mmol/L AGN193109 for 48 hours (5758; Tocris,0
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Molecules Polymerase Chain Reaction Array
The assay was performed according to the manufac-
turer’s instructions of the mouse ECM and the adhesion
molecule array kit (PAMM-013Z; Qiagen, Hilden, Germany).
Data analysis was performed according to manual in-
structions on website http://www.qiagen.com/de/shop/
genes-and-pathways/data-analysis-center-overview-page.Chromatin Immunoprecipitation
The chromatin immunoprecipitation assay was per-
formed as previously described.37 In brief, cells were
cross-linked with 1% (vol/vol) formaldehyde in phosphate-
buffered saline (PBS) for 10 minutes, lysed in 1% (wt/vol)
sodium dodecyl sulfate, and sonicated. Precleared cell ly-
sates were incubated with the antibodies at 4C overnight.
Immune complexes were recovered with salmon sperm
DNA/protein A agarose slurry. After washing and elution,
genomic DNA was extracted with phenol/chloroform for
PCR analysis. Anti-H2AK119ub, Anti-H3K9me2, anti-
H3K27me3, anti-H3K27ac, and anti-H3K4me3 antibodies
were used for chromatin immunoprecipitation; the detailed
antibody information is listed in Table 2. QIAquick PCR
puriﬁcation kit (28104; Qiagen) was used for chromatin
puriﬁcation before ampliﬁcation of promoter regions of
Rarb with qPCR. A detailed primer sequence is listed in
Table 3.Cell Transplantation Experiment
For the orthotopic xenograft models, 1  106 murine
PDAC cells in 100 mL PBS buffer were resuspended and
injected into the pancreatic tails of 8-week-old C57BL/6J
mice. The pancreatic tumors were collected after 4 weeks of
injection. For the portal vein injection models, either 5 
105 cells (399 and 634 cells) or 2  106 (1050 and 10069
cells) in 50 mL PBS buffer were inoculated into the portal
vein of 8-week-old C57BL/6J mice. The entire liver lobes
were collected after 2 weeks of injection. In the tail veinFigure 4. (See previous page). Col6a1 is regulated by glycemi
assay shows cell viability under anchorage-independent state;
array (left panel) and qRT-PCT results (right panel) demonstrate
hypoglycemic PDAC cells; H, high glucose; L, low glucose. (D) W
under anchorage-dependent and -independent states in hyperg
housekeeping gene. (E) Densitometry analysis reveals reduced
tative pictures of H&E staining (left panel) and metastatic area
overexpression restores the ability of metastatic colonization of
staining (left panel) and metastatic area quantiﬁcation (right pan
metastatic colonization in hyperglycemic PDAC cells. (I) Western
PDAC cells and Col6a1 down-regulation in hyperglycemic PDAC
and metastatic area quantiﬁcation (right panel) show that Col6
nization in hyperglycemic PDAC cells. (I) Colony formation (left
liferation rate under anchorage-dependent and -independent sta
cells. (J) Colony formation (left panel) and anoikis assay (right p
and -independent state in control and Col6a1 down-regulated h
uptake rate in Col6a1-overexpressing hypoglycemic cells (L-C
hyperglycemic cells (shCol6a1), and hyperglycemic control ce
tion, and data from 3 independent experiments are shown. Unpainjection models, 1  106 PDAC cells were injected slowly
into the tail vein. The mice were kept for 3 weeks before
PET-CT scanning. The entire lung tissue was collected. All
studies were performed under the agreement of a protocol
approved by the Animal Care and Use Committee of the
Technical University of Munich (55.2.1.54-2532-42-13).Streptozotocin and Metformin
Treatment Experiment
For streptozotocin treatment, 8-week-old C57BL/6J mice
were injected with 50 mg/kg streptozotocin (S0130; Sigma-
Aldrich) for 5 days consecutively as previously described in
http://www.mmpc.org/shared/protocols.aspx when fasting
blood glucose level is higher than 200 mg/dL (deﬁned as
hyperglycemia). These studies were performed within
frame of collaboration with the Department of Gastroen-
terology, Nanjing Drum Tower Hospital, Nanjing University
and approved by local authorities.
For metformin treatment, 8-week-old C57BL/6J mice
received portal vein injection with murine PDAC cells. Then
all animals were daily applied with either saline for the
control group or 250 mg/kg metformin hydrochloride
(PHR1084; Sigma-Aldrich) for 14 days before tissue
collection. All studies were performed under the agreement
of a protocol approved by the Animal Care and Use Com-
mittee of the Technical University of Munich (55.2.1.54-
2532-42-13).Colony Formation Assay
Three  102 PDAC cells were counted and seeded in a
single well of the 6-well plate. After cell adherence, cells
were washed with PBS and incubated with the respective
conditioned medium containing 25 mmol/L or 0.5 mmol/L
glucose for 7 days. A mixture of 75% methanol and 25%
acetone was used for colony ﬁxation. Ten percent crystal
violet was applied for colony staining. The colony number
containing more than 50 cells in every well was counted by
2 independent researchers (Z.J., T.C.).c variability to promote metastatic colonization. (A) Anoikis
H, hyperglycemic cells; L, hypoglycemic cells. (B and C) PCR
altered expression in ECM genes between hyperglycemic and
estern blot analyses show expressions of Col6a1, Spp1, Fn1
lycemic and hypoglycemic PDAC cells; Gapdh is used as a
expression of Col6a1, but not Spp1 and Fn1. (F) Represen-
quantiﬁcation (right panel) results demonstrate that Col6a1
hypoglycemic PDAC cells. (G) Representative pictures of H&E
el) show that Col6a1 down-regulation impairs the capacity of
blot analysis shows Col6a1 overexpression in hypoglycemic
cells. (H) Representative pictures of H&E staining (left panel)
a1 down-regulation impairs the capacity of metastatic colo-
panel) and anoikis assay (right panel) determine the cell pro-
te in control and Col6a1-overexpressing hypoglycemic PDAC
anel) show cell proliferation rate under anchorage-dependent
yperglycemic PDAC cells. (K) 2DG assay determines glucose
ol6a1), hypoglycemic controls (L-C), Col6a1-downregulating
lls (H-C). All data are presented as mean ± standard devia-
ired t test is used to examine statistical signiﬁcance, *P < .05.
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Two  103 PDAC cells were seeded with the 100 mL
respective conditioned medium in 96-well plates. Fifty
mg thiazolyl blue tetrazolium bromide (MTT, M2128;55
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2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 441Live Cell Counting
Two mL PDAC cells in logarithmic phase were trypsi-
nized and seeded in 6-well plate at the concentration of 4 
104/mL. After 24, 48, and 72 hours, cells were trypsinized.
Afterwards, 10 mL cell suspension was mixed with 10 mL
0.4% trypan blue (T10282; Thermo Fischer Scientiﬁc), and
unstained cells (live cells) were counted with a hemocy-
tometer under microscope. The cell concentration and
doubling time were calculated accordingly.
Annexin V and Propidium Iodide Staining
Cells seeded at 100-mm dish were cultured under hypo-
glycemic and hyperglycemic conditions. For quantiﬁcation of
cell apoptosis/necrosis, cells were trypsinized, washed in
PBS, and then resuspended in 1 binding buffer. Cells were
incubated with annexin (A13203; Thermo Fischer Scientiﬁc)
and propidium iodide (P4864; Sigma-Aldrich, Taufkirchen,
Germany) for 15 minutes and analyzed with a FACScan ﬂow
cytometer (BD Biosciences, San Jose, CA).
Invasion and Migration Assay
Cell invasion migration assay was performed by using a
Transwell chamber (354480; Thermo Fischer Scientiﬁc).
Brieﬂy, 2  104 cells were resuspended in 200 mL FBS-free
conditioned medium in the upper chamber; 500 mL normal
conditioned medium (10% FBS) was added to the lower
chamber. After 24 hours, migrated and invaded cells were
ﬁxed with 100% methanol and stained with 10% crystal
violet.
Vascular Endothelial Growth Factor A Enzyme-
linked Immunosorbent Assay Experiment
The same amount of PDAC cells were seeded in a 6-well
plate. After adherence, 1 mL FBS-free conditioned culture
medium was applied on each group for 24 hours. After-
wards, the supernatant was collected for determining
vascular endothelial growth factor A secretion with mouse
vascular endothelial growth factor quantikine enzyme-
linked immunosorbent assay kit (MMV00; R&D Systems,
Wiesbaden, Germany).
Microarray Experiment and Data Analysis
Microarray experiments were performed as previously
described.38 In brief, high- and low-glucose cell samples
were analyzed by Affymetrix GeneChip Mouse Gene 1.0 STFigure 5. (See previous page). Col6a1 is controlled by the Rar
Western blot (right panel) analysis show expression of Runx3; H
RT-PCR analysis shows expression of Runx1 and Runx2 in hy
analysis shows expression of Runx/Col6a1 in another (634 ce
Western blot analysis shows expression of Smad4 and p53
Quantitative RT-PCR analysis shows expression of Rarb (left pan
hypoglycemic cells. (F) Real-time PCR analysis shows expressio
PDAC cells. (G) Mass spectrometry analysis shows intracellular
(H) Quantitative PCR analysis shows expression of Rarb, Run
AGN193109, 50 mmol/L) for 24 hours. (I) Western blot analysis
hibition in hyperglycemic PDAC cells. All data are presented a
experiments are shown. Unpaired t test is applied, *P < .05.microarrays. Normalization was performed according to the
robust multichip average method. A linear model and one-
way analysis of variance were used for identifying differ-
entially expressed genes. Those differentially expressed
genes involved in angiogenesis and the regulation of
angiogenesis were determined through gene ontology
analysis and KEGG analysis.
Glucose Uptake Assay
The same amount of hypoglycemic or hyperglycemic
PDAC cells were seeded and maintained overnight in their
speciﬁc conditioned mediums. Before measurement, cells
were washed 3 times with either KRH buffer (non-radio-
active 2DG-based assay) or PBS buffer (microﬂuidic
radioassay-based assay) and incubated with same amount
of 2DG or 18F-ﬂudeoxyglucose. Afterwards, the glucose
uptake was determined either by a previously published
protocol39 or by a microﬂuidic radioassay system.22 ATP,
ADP, and ADP/ATP ratio were determined by a commercial
EnzyLight ADP/ATP Ratio Assay Kit (ELDT-100; Bioassay
Systems, Hayward, CA).
Anoikis Assay
One  104 cells were seeded and cultured in normal and
ultra-low adherent plate (CLS3473; Sigma-Aldrich) for 48
hours. Afterwards, 50 mL of 250 mg MTT was supplemented
and incubated for 4 hours at 37ºC. The precipitate was
dissolved in cell lysis buffer (10% sodium dodecyl sulfate,
0.01 mol/L HCl), and cell viability was determined by the
absorbance value at 570 nm.
Western Blotting
Twenty mg total proteins was loaded in 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. Then,
proteins were transferred to a polyvinylidene diﬂuoride
membrane (10600002; GE Healthcare, Freiburg, Germany)
and incubated with blocking buffer, ﬁrst antibodies, and
second antibodies subsequently incubation; speciﬁc bands
were detected with the enhanced chemiluminescence sys-
tem (Amersham Life Science Ltd, Bucks, United Kingdom).
The antibodies used are listed in Table 2.
Patient Tissue Collection and Evaluation
The PDAC patients’ tissue were collected, ﬁxed in para-
formaldehyde, and embedded in parafﬁn. The use of theb/Runx3 signal axis. (A) Quantitative RT-PCR (left panel) and
, hyperglycemic cells; L, hypoglycemic cells. (B) Quantitative
perglycemic and hypoglycemic PDAC cells. (C) Western blot
lls) hyperglycemic (H) and hypoglycemic (L) PDAC cells. (D)
in hyperglycemic (H) and hypoglycemic (L) PDAC cells. (E)
el) and its target gene Egr2 (right panel) in hyperglycemic and
n of Rarg and Rara in hyperglycemic (H) and hypoglycemic (L)
levels of RA in hyperglycemic and hypoglycemic PDAC cells.
x3, and Col6a1 after Rar inhibition (by pan-Rar antagonist
shows expression of Rarb, Runx3, and Col6a1 after Rar in-
s mean ± standard deviation, and data from 3 independent
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Figure 6. Rarb relays the signal of glycemic variability to Runx3/Col6a1 via histone modiﬁcation. (A) Sketch view of
chromatin immunoprecipitation (ChIP) assay. (B) ChIP analysis of Rarb gene shows percentage input of H3K9me2,
H2AK119ub, H3K27me3, H3K4me3, and H3K27ac in hyperglycemic and hypoglycemic PDAC cells. Data are presented as
mean ± standard deviation, and data from 3 independent experiments are shown; H, hyperglycemic cells; L, hypoglycemic
cells. (C) Quantitative RT-PCR analysis shows expression of Rarb, Runx3, and Col6a1 after 10 mmol/L, 20 mmol/L SAHA
treatment for 24 hours. Data are presented as mean ± standard deviation, and data from 3 independent experiments are
shown. Unpaired t test is applied, *P < .05. (D) ChIP analysis of Rarb gene shows percentage input of H3K9me2, H3K27me3,
and H3K27ac in control and SAHA treated hypoglyemic (L) PDAC cells. Data are presented as mean ± standard deviation, and
data of 2 independent experiments are shown.
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Figure 7. Rarb relays the signal of glycemic variability to Runx3/Col6a1 via promoter methylation. (A) Methylation-
speciﬁc PCR analysis shows the methylation status of Rarb gene in hypoglycemic PDAC cells, but not in hyperglycemic
PDAC cells; M.SssI, CpG methyltransferase. (B) Quantitative RT-PCR analysis shows the expression of Rarb, Runx3, Col6a1,
and Egr2 after decitabine treatment in hypoglycemic PDAC cells. All data are presented as mean ± standard deviation, and
data from 3 independent experiments are shown. Unpaired t test is applied, *P < .05. (C) Western blot analysis shows
expression of Runx3 and Col6a1 in hypoglycemic 399 (left panel) and 634 (right panel) cells after restoration of hyperglycemic
culturing conditions.
2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 443patient material was approved by the patients before sur-
gery as well as by the local ethics committee (Department of
Surgery, Klinikum rechts der Isar, Technical University of
Munich). Stainings of patients’ tissue were evaluated by 2
independent researchers; the c2 test was performed.Immunohistochemistry Staining and Positive
Cell Calculation
The parafﬁn-embedded tissue sections were deparafﬁ-
nized and rehydrated. Antigen retrieval, endogenous
peroxidase, and non-speciﬁc blocking were performed
before sections were incubated with anti-cleaved caspase-3,
anti-phospho-histone H3, anti-CAIX, anti-CD31, anti-E-
cadherin, anti-COL6A1, and anti-RUNX3 antibodies, respec-
tively. After application of secondary antibodies, sections
were applied with a Liquid DABþ Substrate Chromogen
System (K3468; Dako, Hamburg, Germany) for the color
reaction and with Mayer’s hematoxylin for counterstaining.
Then the sections were dehydrated and mounted, and pic-
tures were taken by a Carl Zeiss microscope (Carl Zeiss,
Munich, Germany) at 5 random views for positive cell
calculation. The number of positively stained cells was
counted by 2 independent researchers with Image J soft-
ware (National Institutes of Health, https://imagej.nih.gov/ij/).
The antibody used is listed in Table 2.Stable Transfection Experiment
For Col6a1 overexpression transfection, hypoglycemic
PDAC cells were transfected with 1 mg of either mouse cDNA
ORF clone (MG223027; OriGene, Herford, Germany) or
control ORF clone (PS100010; OriGene). Then, 0.5 mg/mL
geneticin (10131027; Thermo Fisher Scientiﬁc) was sup-
plemented in culture medium for selection. For Col6a1
stable knock-down transfection, hyperglycemic PDAC cells
were transfected with 1 mg of either COL6A1 shRNA plasmid
(sc-35086-SH; Santa Cruz Biotechnology, Heidelberg, Ger-
many) or control shRNA plasmid (sc-108060; Santa Cruz
Biotechnology). Then, 4 mg/mL puromycin (sc-108071;
Santa Cruz Biotechnology) was supplemented in culture
medium for selection.Mitochondrial Respiration and
Glycolysis Evaluation
Mitochondrial respiration was determined by oxygen
consumption rate, and glycolysis rate was determined by
extracellular acidiﬁcation rate as previously described.40
Brieﬂy, 2  104 hypoglycemic or hyperglycemic cells were
seeded in XF96 culture microplates (101085-004; Agilent
Technologies Deutschland GmbH, Waldbronn, Germany)
overnight at cultivation condition. For basal cellular respi-
ration measurement, cells were treated sequentially with
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Figure 8. PDAC tissues of diabetic patients show increased expression of COL6A1. (A and B) Representative IHC pictures
and statistical analysis show positive rate of RUNX3 and RARB in diabetic and non-diabetic PDAC slides; scale bar, 50 mm. (C)
Representative COL6A1 IHC pictures and statistical analysis show positivity rate of COL6A1 in diabetic and non-diabetic
PDAC slides, scale bar, 50 mm. (D) Representative H&E pictures (left panel) and metastatic area quantiﬁcation (right panel)
show metastatic colonization of PDAC cells in normal (Con) and diabetic samples (STZ). Data are presented as mean ±
standard deviation, and data from 3 independent experiments are shown. Unpaired t test is applied, *P < .05.
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mg/mL), and eventually rotenone/antimycin A (2.5 mmol/L
and 2.5 mmol/L, respectively). Data were acquired by the
Seahorse XF96 analyzer. The oxygen consumption rate and
extracellular acidiﬁcation rate data were analyzed and
interpreted by using Agilent Seahorse Wave 2.4 Software.
The experiments were performed within frame of collabo-
ration with Dr Jastroch (German Center for Diabetes
Research, Helmholtz Zentrum München).
Quantitative Real-Time Polymerase
Chain Reaction
RNA extraction (74104; Qiagen) and cDNA synthesis
(K1632; Thermo Fisher Scientiﬁc) were conducted accord-
ing to the manufacturer’s instructions. Quantitative real-
time PCR was performed by using the KAPA SYBR FAST
Kit (KK4610; Sigma-Aldrich) in a Light-CyclerTM480 sys-
tem. Peptidylprolyl isomerase B was used as housekeeping
gene. Detailed primer sequences are listed in Table 4.
Bisulﬁte Modiﬁcation and Methylation Speciﬁc
Polymerase Chain Reaction
Genomic DNA was isolated from murine PDAC cells
with DNeasy Blood & Tissue Kit (69504; Qiagen). GenomicDNA was modiﬁed with EpiTect Bisulﬁte Kit (59104;
Qiagen) according to manual instructions. Genomic DNA
modiﬁed with CpG methyltransferase (M0226S; Biolabs,
Frankfurt am Main, Germany) was used as positive control.
Methylation speciﬁc PCR analyses and the according
primers were used as described before.41 Afterwards,
methylation speciﬁc PCR analyses were described as fol-
lows: 95C 5 minutes, 40 cycles of thermocycling: 95C 30
seconds, 56.5C 30 seconds, 72C 45 seconds, and ended
with 72C for 5 minutes.
Measurement of Intracellular Uptake of Retinoid
Acid by Mass Spectrometry
Two  105 399 cells were plated either in low-glucose
medium or in high-glucose medium. After 24 hours, 100
mmol/L RA (Sigma-Aldrich; R2625) was added in the dark.
After additional 48 hours, the remaining cells were washed
with 0.5 mL PBS and harvested with 300 mL ice-cold iso-
propanol. Afterwards, the cells were sonicated, vortexed,
and stored in dark tubes at –80C. To prevent isomerization
of the RA, amber glassware was used. Before measurement,
the samples were centrifuged for 5 minutes at 4C with
13,000 rpm to remove cell debris. The supernatant was
directly used for liquid chromatography–mass spectrometry
analysis.
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Figure 9. Activity of the Rarb/Runx3/Col6a1 signal axis is inhibited by metformin. Quantitative RT-PCR results show
expression of Rarb, Runx3, and Col6a1 after metformin (20 mmol/L) and 2DG (10 mmol/L) treatment for 48 hours in hypergly-
cemic PDAC cells. (B) Western blot analysis shows expression of Rarb, Runx3, Col6a1, and phospho-AMPKaThr172 after met-
formin and 2DG treatment for 48 hours in hyperglycemic PDAC cells. (C) Quantitative RT-PCR analysis shows expression of
Runx1, Runx2, Rara, Rarg, and Egr2 after metformin (20 mmol/L) and 2DG (10 mmol/L) treatment for 48 hours in hyperglycemic
PDAC cells. (D) Glucose uptake assay shows reduced cellular uptake after metformin treatment for 24 hours. (E) Representative
H&E pictures (left panel) and metastatic area quantiﬁcation (right panel) show metastatic colonization in control and metformin
treated hyperglycemic PDAC cells. All data are presented as mean ± standard deviation; data of 3 independent experiments are
shown. Unpaired t test is applied, *P < .05. (F) Chromatin immunoprecipitation (ChIP) analysis of Rarb gene shows percentage
input of H3K9me2, H3K27me3, and H3K27ac in control and metformin treated hyperglycemic PDAC cells. All data are presented
as mean ± standard deviation, and data from 2 independent experiments are shown. H, hyperglycemic cells; Met, metformin.
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Table 2.Antibody List
Antibody name Catalogue number Application Producer
Rabbit anti-p-histone H3 (Ser10) Ab 9701 IHC Cell Signaling Technology
Rabbit anti-cleaved Casp3 mAb 9664 IHC Cell Signaling Technology
Rat anti-Cd31 Ab DIA-310 IHC Dianova (Hamburg, Germany)
Rabbit anti-GAPDH Ab sc-25778 WB Santa Cruz
Rabbit anti-carbonic anhydrase IX Ab ab15086 IHC Abcam
Rabbit anti-COL6A1 Ab (H-200) sc-20649 IHC WB Santa Cruz
Rabbit anti-ﬁbronectin 1 C-terminal Ab Sab4500974 WB Sigma-Aldrich
Mouse anti-OPN Ab (LFMb-14) SC-73631 WB Santz Cruz
Mouse anti-RUNX3/AML2 (D9K6L) mAb 13089s WB IHC Cell Signaling Technology
Mouse anti-RARb2 Ab (B-12) SC-514585 WB Santa Cruz
Mouse anti-RARB Ab clone 11E8.1 MABC302 IHC Merck (Darmstadt, Germany)
Rabbit anti-p-AMPKa (Thr172) mAb 2535 WB Cell Signaling Technology
Rabbit anti-ubiquityl-histone H2A (Lys119) (D27C4) mAb 8240 ChIP Cell Signaling Technology
Mouse anti-histone H3 (di-methyl K9) Ab
[mAbcam 1220] - ChIP grade
ab1220 ChIP Abcam (Cambridge, UK)
Mouse anti-histone H3 (tri-methyl K27) Ab
[mAbcam 6002] - ChIP grade
ab6002 ChIP Abcam
Rabbit anti-histone H3 (acetyl K27) Ab - ChIP grade ab4729 ChIP Abcam
Rabbit anti-tri-methyl-histone H3 (Lys4) (C42D8) mAb 9751 ChIP Cell Signaling Technology
ChIP, chromatin immunoprecipitation; WB, Western blot.
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chromatography–mass spectrometry analysis by using a
Prominence HPLC system (Shimadzu, Hannover, Germany)
and a 4000 QTRAP (Applied Biosystems, Foster City, CA).
The separation was performed by using a 100  2.1 mm
inner diameter, 5 mm Kinetex 5u XB-C18 100 A column
(Phenomenex, Aschaffenburg, Germany) with a 300 mL/min
ﬂowrate and a linear gradient from 50% A (A: acetonitrile/
isopropanol/water with 5 mmol/L ammonia acetate [55/
40/5, v/v/v, pH 5], B: 5 mmol/L ammonia acetate [pH 5])
for 1 minute to 100% A in 8 minutes, which was maintained
for 4 minutes. Afterwards, the column was equilibrated to
starting conditions. Ions were analyzed by mass spectrom-
etry in the positive mode using a Turbo V Ion Source
(Applied Biosystems) in the APCI mode. The nebulizer
current was set to 5 mA at a source temperature of 300CTable 3.Sequences of Primers for Rarb Chromatin Immunopre
Name Sense (50/30)
Pair1 ATACTGCTCCACCCCAGGA
Pair2 CACGCTGAGCTTCCTATGC
Pair3 AGCGAGCCTGGAAAATGGT
ratio ¼ metastasis area in ðmedianþ l
total area ðmedianþ left þand using nitrogen as collision gas. The parameters for the
collision activated dissociation were medium, curtain gas:
20 psi, ion source gas 1: 90 psi, declustering potential 31 V,
entrance potential 10 V. The multiple reaction monitoring
transition 301.23/ 123.10 (collision energy 7 V, cell exit
potential 14 V) was used as quantiﬁer, and 301.23/ 80.90
(collision energy 23 V, cell exit potential 10 V) was used as
qualiﬁer. The quantiﬁcation was performed by using an
external calibration from 0.1 to 500 mmol/L RA.Liver Metastasis Area Analysis
The tissue sections were scanned with a 1.25 object of
a Zeiss microscope. The tumor’s metastasis area and total
liver area were counted by Image J (1.48v). The metastasis
area ratio was calculated as follows:cipitation Analysis
Antisense (50/30)
A GCCATGGGCAATTAAGGCAG
T GTACACCCACCCTTGCTGAA
AA CTCCATCAAACTCTGCCCCT
eft þ right þ caudateÞ lobe
right þ caudate Þ lobe  100%
Table 4.Sequences of Primers for qRT-PCR Analysis
Name Sense (50/30) Antisense (50/30)
Spp1 AAGAAGCATCCTTGCTTGGGT ATGGTCGTAGTTAGTCCTTGGC
Col6a1 CAGCCAGACCATTGACACCA TTCCTCGCTCCCCCTCATAC
Fn1 ATGTGGACCCCTCCTGATAGT GCCCAGTGATTTCAGCAAAGG
Ppib GGAGCGCAATATGAAGGTGC CTTATCGTTGGCCACGGAGG
Rara ATCTGTGGAGACCGACAGGA CCGTTTCCGGACGTAGACTT
Rarb CAAGACACCGAGGTTGTGGA ACAGAGGCCCTGGTTCCTTA
Rarg TGCTGCGGATCTGTACAAGG TTGTGCATCTGGGTTCGGTT
Runx3 AGAGTTTCACGCTCACAATC GGAGAAGGGGTTCAGGTC
Egr2 GCCAAGGCCGTAGACAAAATC CCACTCCGTTCATCTGGTCA
Runx1 TTTGGGGTGCATCAGTGTGA AACCAGCGGTTAGGCTTCAT
Runx2 GGGAACCAAGAAGGCACAGA GGATGAGGAATGCGCCCTAA
2018 Signal Axis of Rarb/Runx3/Col6a1 in PDAC 447Positron Emission Tomography/Computed
Tomography Scan
The animals were anesthetized with isoﬂurane and
imaged by using the Siemens Inveon microPET/CT (Siemens
Healthcare, Erlangen, Germany). Fifty minutes before the
PET scan, 10–15 MBq 18F-ﬂudeoxyglucose was injected
intravenously. All measurements were corrected for phys-
ical decay, dead time, and non-uniformity of microPET
response, and the images were reconstructed by using the
3-dimensional ordered subset expectation maximization
algorithm. The standard uptake values were calculated by
normalizing the injection dose and the body weight. Regions
of interest were deﬁned manually on the basis of the fusion
of CT and PET images by using PMOD software (version 3.1;
PMOD Technologies, Zurich, Switzerland).Cellular Microﬂuidic Radioassay
A continuously infused microﬂuidic radioassay system
was used to measure real-time cellular uptake.22 Two days
before the continuously infused microﬂuidic radioassay
measurements, approximately 1.5  104 cells in 30 mL
suspension were inoculated into the cell culture chamber of
a microﬂuidic chip (m-Slide VI0.4; ibidi GmbH, Munich,
Germany) and formed a homogeneity single layer on the
bottom surface of the chamber. The cells were then cultured
in 25 mmol/L glucose Dulbecco modiﬁed Eagle medium
(Biochrom GmbH, Berlin, Germany), supplemented with
10% FBS, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin at controlled condition of 37ºC and 5% CO2. One day
before the measurements, the cell chamber for low-glucose
medium was changed with 0.5 mmol/L glucose concentra-
tion separately. The corresponding medium was exchanged
every 8 hours until the start of the measurements to sustain
glucose concentration. At the time of the continuously
infused microﬂuidic radioassay measurements, the cells
reached approximately 60%–90% conﬂuence inside the cell
chamber. Before the infusion, the ﬂow control unit (Cavro
XLP 6000; Tecan Group Ltd, Männedorf, Switzerland) was
sterilized and cleaned by using 70% ethanol and ultrapure
water. [18F]Fludeoxyglucose was diluted into the cellculture medium to generate a radioactive solution of 0.2–5
MBq/mL with the culturing glucose concentration. The
tracer medium solution was pumped through the medium
chamber and cell chamber at a constant ﬂow of 1.25 ml/s.
Positrons emitted both from the medium chamber and the
cell chamber were measured by the positron camera (Crytur
Ltd, Turnov, Czech Republic) for 75 minutes. Measurements
were binned into frames of 1 minute each. Each measure-
ment was repeated 6 times. After the continuously infused
microﬂuidic radioassay measurements, the cell chamber
was imaged by using a microscope (BZ-9000; Keyence Co
Ltd, Osaka, Japan), and 5 distributed ﬁelds of view were
selected for counting the number of cells. The average
number of cells per detector pixel was calculated.Statistical Analysis
Statistical analysis was performed by GraphPad Prism 6
(GraphPad, La Jolla, CA) or IBM SPSS 22.0 Software (Sta-
tistical Package for the Social Sciences; IBM, New York, NY).
All experiments were performed independently at least 3
times. Unless otherwise stated, an unpaired Student t test
was used for group-wise comparisons of 2 groups. The data
signiﬁcance level was set at P < .05. Results are expressed
as mean ± standard deviation unless indicated otherwise.References
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